Summary
Pfizer Inc. (PFE) has officially completed its acquisition of Hospira, Inc., a leader in injectable drugs and infusion technologies, through a merger that became effective on September 3, 2015. This strategic move sees Hospira become a wholly-owned subsidiary of Pfizer. Under the terms of the merger, Hospira shareholders will receive $90.00 in cash for each share of Hospira common stock they hold, excluding certain treasury, PFE-owned, or dissenting shares. This acquisition significantly enhances Pfizer's business, particularly in the area of biosimilars and sterile injectable products, aligning with the company's strategy to expand its portfolio and market presence in key therapeutic areas. Investors should note that this is a cash-and-carry transaction, meaning no stock is being issued by Pfizer, and the financial impact will be primarily through the integration of Hospira's operations and its contribution to Pfizer's revenue and earnings.
Key Highlights
- 1Pfizer Inc. completed the acquisition of Hospira, Inc. on September 3, 2015.
- 2Hospira is now a wholly-owned subsidiary of Pfizer.
- 3Hospira shareholders will receive $90.00 in cash per share.
- 4The merger was executed via an Agreement and Plan of Merger dated February 5, 2015.
- 5This acquisition strengthens Pfizer's position in biosimilars and sterile injectables.
- 6The filing includes an exhibit of the press release announcing the merger completion.